United States, Rockville MD, Aug. 04, 2022 (GLOBE NEWSWIRE) -- As per industry analysis by Fact.MR, a market research and competitive intelligence provider, the global neuroprotection therapeutics market is expected to reach a valuation of US$ 85.1 billion by 2027, rising at a CAGR of 6.8% over the forecast period (2022-2027).
A complex biochemical process called neuroprotection, or the prevention of neuronal loss, is controlled by numerous cellular pathways. Trauma, stress, hemorrhage, infection, traumatic brain injury (TBI), and burst brain aneurysm are the most frequent conditions linked to nervous system involvement and intensive care unit (ICU) admission.
For Critical Insights on Neuroprotection Therapeutics Market, Request a Sample Report
https://www.factmr.com/connectus/sample?flag=S&rep_id=7564
Through acts on the brain rather than by enhancing blood flow, neuroprotection refers to the use of medicines that lessen brain injury after acute stroke. A number of neuroprotective drugs have undergone thorough preclinical to clinical trial transitions. Neurological diseases are one of the main causes of disability and death in the world. Treatments that support maintaining the structure and functionality of neurons are known as neuroprotection therapeutics.
Stroke and traumatic brain injury, both result in secondary metabolic changes in the brain. Both, tissue damage and neuronal cell death result from this. Neuroprotection therapeutics assist patients in preventing further tissue loss and enhancing their behavioral outcomes. Government organizations are paying more attention and taking the necessary actions to create or improve their healthcare infrastructure and advance therapeutic delivery.
Why is Demand for Neuroprotection Therapeutics Rising Rapidly?
“Implementation of Medical Professional Training Programs in Healthcare Facilities to Surge Adoption of Neuroprotection Therapeutics”
The market for neuroprotection therapeutics may see many potential opportunities due to technological developments in the healthcare industry and the rising demand for innovative neuroprotective products in light of considerable research on drugs for the effective preservation of brain cells.
Therapeutics for neuroprotection offer drugs that shield the brain and central nervous system. These products work well to regenerate cells that may have been damaged by trauma or stress. These features and advantages could significantly boost the market for neuroprotection therapeutics.
The market for neuroprotection treatments is expected to rise due to the steadily growing senior population and the increased occurrence of disorders affecting the central nervous system.
To learn more about Neuroprotection Therapeutics Market, you can get in touch with our Analyst at https://www.factmr.com/connectus/sample?flag=AE&rep_id=7564
Key Segments Covered in the Neuroprotection Therapeutics Industry Survey
- By Product :
- Free Radical Trapping Agents (Antioxidants)
- Glutamate Antagonists (Anti-Excitotoxic Agents)
- Apoptosis Inhibitors
- Anti-inflammatory Agents
- Neurotrophic Factors (NTFs)
- Other Products
- Free Radical Trapping Agents (Antioxidants)
- By Medical Condition :
- Alzheimer's Disease
- Dementia
- Epilepsy
- Multiple Sclerosis
- Alzheimer's Disease
- By Application :
- Prevention
- Treatment
- Prevention
- By End User :
- Hospitals
- Clinics
- Others
- Hospitals
- By Region :
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
- North America
Competitive Landscape
Several businesses have increased their research and development efforts to develop therapeutic drugs for neurological disorders as a result of the increase in neurological ailments. The most promising treatments for neurological illnesses have received applications from various companies across the world, and they are currently undergoing different stages of regulatory approval.
For instance,
- Dr. Reddy's Laboratories Limited engaged in a distribution arrangement with Integra Life Sciences Holdings Corporation to market and promote Integra's neurological disorder medications in India.
Get Customization on Neuroprotection Therapeutics Market Report for Specific Research Solutions
https://www.factmr.com/connectus/sample?flag=RC&rep_id=7564
Key players in the Neuroprotection Therapeutics Market
- Allergan PLC
- Daiichi Sankyo Co., Ltd.
- Astrocyte Pharmaceuticals Inc.
- AstraZeneca PLC
- Biogen, Inc.
- Novartis International AG
- Eli Lilly and Company
- F. Hoffmann-La Roche AG
Key Takeaways from Neuroprotection Therapeutics Market Study
- The global neuroprotection therapeutics market is currently valued at US$ 61.25 billion.
- The market in Japan is anticipated to expand at a CAGR of 6.4% over the forecast period.
- Demand for glutamate antagonists is expected to surge at a CAGR of 7.1% from 2022 to 2027.
- The market in Europe is projected to increase at a CAGR of 5.5% over the decade.
About the Healthcare Division at Fact.MR
Our healthcare consulting team guides organizations at each step of their business strategy by helping you understand how the latest influencers account for operational and strategic transformation in the healthcare sector. Our expertise in recognizing the challenges and trends impacting the global healthcare industry provides indispensable insights and support - encasing a strategic perspective that helps you identify critical issues and devise appropriate solutions.
Explore Fact.MR's Coverage on the Healthcare Domain-
Point of Care Diagnostics Market - Shipments of point of care test (POCT) kits are projected to surge at a CAGR of around 7% from 2021 to 2028, as per this new analysis. In 2020, the global point of care diagnostics market stood at US$ 34.1 Bn, and is anticipated to surge to a valuation of US$ 66 Bn by the end of 2028.
Spectrometry Market - The global spectrometry market is projected to increase from a valuation of US$ 7.1 Bn in 2020 to US$ 13.8 Bn by 2028, expanding at a CAGR of 6.4% during the forecast period, Demand for mass spectrometry is set to increase faster at a CAGR of 7.4% over the forecast period 2021-2028.
Coronary Stents Market- Worldwide sales of coronary stents were valued at around US$ 10.1 Bn in 2020. The global coronary stents market is projected to register 12.9% CAGR and reach a valuation of US$ 25.7 Bn by the end of 2028.
Osteoporosis Therapeutics Market- The global osteoporosis therapeutics market stands at a valuation of US$ 12.7 Bn currently, and is predicted to reach US$ 14.2 Bn by the end of 2026. Consumption of osteoporosis therapeutic drugs is anticipated to increase at a CAGR of 2.9% from 2022 to 2026.
CNS Therapeutics Market- The CNS therapeutics market stands at a valuation of US$ 116.7 Bn in 2022, and is expected to reach US$ 142.1 Bn by the end of 2026. CNS drug sales are projected to rise at a steady CAGR of 4.9% from 2022 to 2026.
Induced Pluripotent Stem Cell (iPSC) Market- The global induced pluripotent stem cell (iPSC) market stands at a valuation of US$ 1.8 Bn in 2022, and is projected to climb to US$ 2.3 Bn by the end of 2026. Over the 2022 to 2026 period, worldwide demand for induced pluripotent stem cells is anticipated to rise rapidly at a CAGR of 6.6%.
Doxorubicin Market- Demand for doxorubicin is anticipated to increase steadily at a CAGR of 5.3% from 2022 to 2026. At present, the global doxorubicin market stands at US$ 1.1 Billion, and are projected to reach a valuation of US$ 1.3 Billion by the end of 2026.
Heart Attack Diagnostics Market- The heart attack diagnostics market is predicted to grow at a moderate CAGR of 7.1% during the forecast period of 2022 to 2032. The global heart attack diagnostics market is estimated to reach a value of nearly US$ 22.2 Billion by 2032 by growing from US$ 10.4 Billion in 2021.
Smart Implants Market- The global smart implants market is estimated at US$ 3.9 billion in 2022, and is forecast to surpass a market value of US$ 22.2 billion by 2032. Smart implants are expected to contribute significantly to the global implants market, with demand surging at a CAGR of 19% from 2022 to 2032.
Facial Implants Market- The global facial implant market was valued at US$ 2.7 Billion in 2022, and is expected to rise at a 7.7% value CAGR, likely to reach US$ 5.6 Billion by the end of the 2022-2032 forecast period.
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
Mahendra Singh
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
Email: sales@factmr.com
Tel: +1 (628) 251-1583
Follow Us: LinkedIn | Twitter
